Polyunsaturated fatty acids and cardiovascular disease: Implications for nutrigenetics

Journal of Nutrigenetics and Nutrigenomics

Volumn 2, Issue 3, 2009, Pages 140-148

  Allayee, Hooman ^a,b   Roth, Nitzan ^a   Hodis, Howard N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Institute for Genetic Medicine

Author keywords

5 Lipoxygenase; Cardiovascular disease; Fatty acids; Genes; Leukotriene

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LINOLEIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; FATTY ACID METABOLISM; GENETIC ASSOCIATION; GENETIC TRAIT; HEART PROTECTION; HUMAN; LIPID DIET; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; RISK FACTORS;

MUS;

EID: 70349258116     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000235562     Document Type: Short Survey

References (69)

1. Lusis AJ: Atherosclerosis. Nature 2000; 407: 233-241.
2. Lusis AJ, Weinreb A, Drake TA, Allayee H: Genetics of atherosclerosis; in Topol EJ (ed): Textbook of Cardiovascular Disease. Philadelphia, Lippincott-Raven, 2002, chapter 98.
3. National Human Genome Research Institute (NHGRI): A catalog of published genomewide association studies. www.genome.gov/ gwastudies (accessed 17 August 2009).
4. Bezard J, Blond JP, Bernard A, Clouet P: The metabolism and availability of essential fatty acids in animal and human tissues. Reprod Nutr Dev 1994; 34: 539-568.
5. Simopoulos AP: The importance of the omega- 6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008; 233: 674-688.
6. Nakamura MT, Nara TY: Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 2004; 24: 345-376.
7. Brenna JT: Efficiency of conversion of alphalinolenic acid to long chain n-3 fatty acids in man. Curr Opin Clin Nutr Metab Care 2002; 5: 127-132.
8. Wijendran V, Hayes KC: Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Annu Rev Nutr 2004; 24: 597-615.
9. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP: Compartmental modeling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses. J Lipid Res 2005; 46: 1474-1483.
10. Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002; 277: 8755-8758.
11. Leaf A, Kang JX, Xiao YF: Fish oil fatty acids as cardiovascular drugs. Curr Vasc Pharmacol 2008; 6: 1-12.
12. Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS: Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008; 83: 324-332.
13. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ: Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 2008; 197: 12-24.
14. Massaro M, Scoditti E, Carluccio MA, De Caterina R: Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 109-115.
15. Vila L: Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: Role in atherosclerosis. Med Res Rev 2004; 24: 399-424.
16. Mori TA, Beilin LJ: Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004; 6: 461-467.
17. Calder PC: N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83: 1505S-1519S.
18. Peters-Golden M, Brock TG: Intracellular compartmentalization of leukotriene biosynthesis. Am J Respir Crit Care Med 2000; 161:S36-S40.
19. Peters-Golden M, Henderson WR Jr: Leukotrienes. N Engl J Med 2007; 357: 1841-1854.
20. Back M, Hansson GK: Leukotriene receptors in atherosclerosis. Ann Med 2006; 38: 493-502.
21. Radmark O, Samuelsson B: 5-lipoxygenase: Regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat 2007; 83: 162-174.
22. Nakahata N: Thromboxane A2: Physiology/ pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008; 118: 18-35.
23. von Schacky C: Prophylaxis of atherosclerosis with marine omega-3 fatty acids. A comprehensive strategy. Ann Intern Med 1987; 107: 890-899.
24. Terano T, Salmon JA, Moncada S: Biosynthesis and biological activity of leukotriene B5. Prostaglandins 1984; 27: 217-232.
25. Mehrabian M, Allayee H: 5-Lipoxygenase and atherosclerosis. Curr Opin Lipidol 2003; 14: 447-457.
26. Tymchuk CN, Hartiala J, Patel PI, Mehrabian M, Allayee H: Nonconventional genetic risk factors for cardiovascular disease. Curr Atheroscler Rep 2006; 8: 184-192.
27. Mehrabian M, Wong J, Wang X, et al: Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 2001; 89: 125-130.
28. Mehrabian M, Allayee H, Wong J, et al: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91: 120-126.
29. Zhao L, Moos MP, Grabner R, et al: The 5- lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10: 966-973.
30. Poeckel D, Zemski Berry KA, Murphy RC, Funk CD: Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice. J Biol Chem 2009; 284: 21077-21089.
31. Cao RY, St Amand T, Grabner R, Habenicht AJ, Funk CD: Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009; 203: 395-400.
32. Mehrabian M, Allayee H, Stockton J, et al: Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat Genet 2005; 37: 1224-1233.
33. Mehrabian M, Schulthess FT, Nebohacova M, et al: Identification of ALOX5 as a gene regulating adiposity and pancreatic function. Diabetologia 2008; 51: 978-988.
34. Spanbroek R, Grabner R, Lotzer K, et al: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-1243.
35. Qiu H, Gabrielsen A, Agardh HE, et al: Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006; 103: 8161-8166.
36. Sanchez-Galan E, Gomez-Hernandez A, Vidal C, et al: Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res 2009; 81: 216-225.
37. Wingrove JA, Daniels SE, Sehnert AJ, et al: Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet 2008; 1: 31-38.
38. Dwyer JH, Allayee H, Dwyer KM, et al: Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350: 29-37.
39. Allayee H, Baylin A, Hartiala J, et al: Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction. Am J Clin Nutr 2008; 88: 934-940.
40. Gonzalez P, Reguero JR, Lozano I, Moris C, Coto E: A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int J Immunogenet 2007; 34: 127-130.
41. Maznyczka A, Braund P, Mangino M, Samani NJ: Arachidonate 5-lipoxygenase (5-LO) promoter genotype and risk of myocardial infarction: A case-control study. Atherosclerosis 2008; 199: 328-332.
42. Baylin A, Kabagambe EK, Ascherio A, Spiegelman D, Campos H: Adipose tissue alphalinolenic acid and nonfatal acute myocardial infarction in Costa Rica. Circulation 2003; 107: 1586-1591. (Pubitemid 36397325)
43. Carlson CS, Heagerty PJ, Nord AS, et al: Tag- SNP evaluation for the association of 42 inflammation loci and vascular disease: Evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects. Hum Genet 2007; 121: 65-75.
44. Crosslin DR, Shah SH, Nelson SC, et al: Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Hum Genet 2009; 125: 217-229.
45. Helgadottir A, Manolescu A, Thorleifsson G, et al: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-239.
46. Helgadottir A, Gretarsdottir S, St Clair D, et al: Association between the gene encoding 5- lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76: 505-509.
47. Girelli D, Martinelli N, Trabetti E, et al: ALOX5AP gene variants and risk of coronary artery disease: An angiography-based study. Eur J Hum Genet 2007; 15: 959-966.
48. Linsel-Nitschke P, Gotz A, Medack A, et al: Genetic variation in the arachidonate 5-lipoxygenase- activating protein (ALOX5AP) is associated with myocardial infarction in the German population. Clin Sci (Lond) 2008; 115: 309-315.
49. van der Net JB, Versmissen J, Oosterveer DM, et al: Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia. Atherosclerosis 2009; 203: 472-478.
50. Helgadottir A, Manolescu A, Helgason A, et al: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38: 68-74.
51. Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM: Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: A nested case-control approach. Stroke 2006; 37: 2007-2011.
52. Koch W, Hoppmann P, Mueller JC, Schomig A, Kastrati A: No association of polymorphisms in the gene encoding 5-lipoxygenase- activating protein and myocardial infarction in a large central European population. Genet Med 2007; 9: 123-129.
53. Assimes TL, Knowles JW, Priest JR, et al: Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum Genet 2008; 123: 399-408.
54. Hakonarson H, Thorvaldsson S, Helgadottir A, et al: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: A randomized trial. JAMA 2005; 293: 2245-2256.
55. Jawien J, Gajda M, Rudling M, et al: Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006; 36: 141-146.
56. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ: Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002; 22: 443-449.
57. Subbarao K, Jala VR, Mathis S, et al: Role of leukotriene B4 receptors in the development of atherosclerosis: Potential mechanisms. Arterioscler Thromb Vasc Biol 2004; 24: 369-375.
58. Huang L, Zhao A, Wong F, et al: Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol 2004; 24: 1783-1788.
59. Heller EA, Liu E, Tager AM, et al: Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005; 112: 578-586.
60. Iovannisci DM, Lammer EJ, Steiner L, et al: Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: The Muscatine Study. Arterioscler Thromb Vasc Biol 2007; 27: 394-399.
61. Freiberg JJ, Dahl M, Tybjaerg-Hansen A, Grande P, Nordestgaard BG: Leukotriene C4 synthase and ischemic cardiovascular disease and obstructive pulmonary disease in 13,000 individuals. J Mol Cell Cardiol 2009; 46: 579-586.
62. Bevan S, Dichgans M, Wiechmann HE, Gschwendtner A, Meitinger T, Markus HS: Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: A replication study in two independent populations. Stroke 2008; 39: 1109-1114.
63. Allayee H, Hartiala J, Lee W, et al: The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 2007; 132: 868-874.
64. Jawien J, Gajda M, Wolkow P, Zuranska J, Olszanecki R, Korbut R: The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2008; 59: 633-639.
65. Kang JX: Fat-1 transgenic mice: A new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 263-267.
66. Hudert CA, Weylandt KH, Lu Y, et al: Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006; 103: 11276-11281.
67. Connor KM, SanGiovanni JP, Lofqvist C, et al: Increased dietary intake of omega-3- polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007; 13: 868-873.
68. Berquin IM, Min Y, Wu R, et al: Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007; 117: 1866-1875.
69. Mayer K, Kiessling A, Ott J, et al: Acute lung injury is reduced in fat-1 mice endogenously synthesizing n-3 fatty acids. Am J Respir Crit Care Med 2009; 179: 474-483.